Quanterix/$QTRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Quanterix
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.
Ticker
$QTRX
Sector
Primary listing
Employees
450
Headquarters
Website
Quanterix Metrics
BasicAdvanced
$164m
-
-$2.33
1.15
-
Price and volume
Market cap
$164m
Beta
1.15
52-week high
$8.77
52-week low
$2.40
Average daily volume
843k
Financial strength
Current ratio
3.722
Quick ratio
2.536
Long term debt to equity
9.713
Total debt to equity
12.524
Profitability
EBITDA (TTM)
-63.673
Gross margin (TTM)
45.31%
Net profit margin (TTM)
-71.86%
Operating margin (TTM)
-56.38%
Effective tax rate (TTM)
2.08%
Revenue per employee (TTM)
$320,000
Management effectiveness
Return on assets (TTM)
-13.39%
Return on equity (TTM)
-34.81%
Valuation
Price to revenue (TTM)
1.073
Price to book
0.58
Price to tangible book (TTM)
1.12
Price to free cash flow (TTM)
-1.877
Free cash flow yield (TTM)
-53.29%
Free cash flow per share (TTM)
-1.854
Growth
Revenue change (TTM)
6.85%
Earnings per share change (TTM)
87.51%
3-year revenue growth (CAGR)
11.56%
3-year earnings per share growth (CAGR)
-0.84%
What the Analysts think about Quanterix
Analyst ratings (Buy, Hold, Sell) for Quanterix stock.
Quanterix Financial Performance
Revenues and expenses
Quanterix Earnings Performance
Company profitability
Quanterix News
AllArticlesVideos
Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·2 weeks ago
Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages
Business Wire·3 weeks ago
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.